Concentrix price target lowered to $61 from $65 at BofA

BofA lowered the firm’s price target on Concentrix (CNXC) to $61 from $65 and keeps a Neutral rating on the shares after the company reported better-than-expected fiscal Q2 revenue, but its operating margin missed guidance despite the revenue beat due to negative operating leverage from the decision to hold labor intact in April for certain paused client programs resulting from tariff uncertainty and investments to prepare for higher growth in the second half of the fiscal year. The firm bases its updated price target on an unchanged multiple applied to its calendar 2026 EPS estimate of $12.16, down from a prior $12.32 forecast.